1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

NAVIDEA BIOPHARMACEUTICALS INC. (NAVB) CEO Mark Jerome Pykett buys 1,850 Shares

March 18, 2013 | About:

Pres. & CEO of NAVIDEA BIOPHARMACEUTICALS INC. (NAVB) Mark Jerome Pykett buys 1,850 shares of NAVB on 03/15/2013 at an average price of $2.7 a share.

Navidea Biopharmaceuticals Inc has a market cap of $303 million; its shares were traded at around $2.82 with and P/S ratio of 3520.7.

This is the annual revenues and earnings per share of NAVB over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of NAVB.


CEO Recent Trades:



  • Pres. & CEO Mark Jerome Pykett bought 1,850 shares of NAVB stock on 03/15/2013 at the average price of 2.7. Mark Jerome Pykett owns at least 358,212 shares after this. The price of the stock has increased by 4.44% since.

This is the insider trade history vs. stock price of NAVB. For the complete insider trading history of NAVB, click here.




Directors and Officers Recent Trades:



  • Director Brendan A Ford bought 5,000 shares of NAVB stock on 03/15/2013 at the average price of 2.71. Brendan A Ford owns at least 119,250 shares after this. The price of the stock has increased by 4.06% since.
  • SVP-Global Regulatory Strategy William J. Regan bought 5,000 shares of NAVB stock on 03/15/2013 at the average price of 2.71. William J. Regan owns at least 5,000 shares after this. The price of the stock has increased by 4.06% since.
  • EVP & Chief Business Officer Thomas H. Tulip bought 17,500 shares of NAVB stock on 03/15/2013 at the average price of 2.82. Thomas H. Tulip owns at least 45,940 shares after this. The price of the stock has decreased by 0% since.
  • Director Gordon A Troup bought 7,000 shares of NAVB stock on 03/15/2013 at the average price of 2.7. Gordon A Troup owns at least 126,250 shares after this. The price of the stock has increased by 4.44% since.
  • 10% Owner Life Sciences Platinum-montaur sold 708,382 shares of NAVB stock on 09/21/2012 at the average price of 3.7. Life Sciences Platinum-montaur owns at least 6,801,016 shares after this. The price of the stock has decreased by 23.78% since.


For the complete insider trading history of NAVB, click here.
  • CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
  • Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
  • Double Buys:: Companies that both Gurus and Insiders are buying
  • Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.

» Take a Free Trial of Premium Membership


Rating: 4.0/5 (1 vote)

Comments

Please leave your comment:


Select portfolio(s):

  • Loading...

Why you are interested?

Your selection and notes will be stored in your portfolio.

Login to add portfolio
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK